S&P 500 Rises Over 1%; General Motors Earnings Top Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.8% on Tuesday.
Astellas to Invest a Total of $50M to acquire 15% of Taysha Gene Therapies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Taysha Gene Therapies, Inc. (NASDAQ: TSHA, CEO: RA Session II, "Taysha") today announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Chardan Capital Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $32
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $34 to $32.
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $16
Goldman Sachs maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $27 to $16.
Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $20
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $32 to $20.